comparemela.com

Latest Breaking News On - Asitinib - Page 3 : comparemela.com

Masitinib receives orphan drug status for the treatment of

PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm.

United-states
Paris
France-general
France
Switzerland
Olivier-hermine
European-medicines-agency
Drug-administration
Scientific-committee
Swiss-agency-for-therapeutic-products-swissmedic
Swiss-agency
Therapeutic-products

AB Science announces the drawdown of the first tranche of 6

PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT.

Paris
France-general
France
European-investment-bank
Euronext-paris
Paris-stock-exchange-ab
Ab-science
Asitinib
Covid-19

AB Science receives first agencies authorizations to

PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF.

France
Paris
France-general
Spain
Greece
French
Bruno-dubois
Olivier-hermine
French-medicine-agency
Professor-of-neurology-at-sorbonne-university
Scientific-committee
Daily-living

AB Science today reports its revenues for the first half of

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2022 AND THE KEY EVENTS OF THE PERIOD Clinical development.

France
Paris
France-general
Canada
French
Canadians
French-medicine-agency
Health-canada-adjudicating-committee
European-medicines-agency
Health-canada
Committee-for-medicinal-products-human-use

AB Science announces that it has filed an application for

PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FOR ALSITEK IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.

United-states
Paris
France-general
France
Scler-frontotemporal-degener
Alain-moussy
European-medicines-agency
Committee-for-medicinal-products-human-use
Marketing-authorization
Medicinal-products
Human-use
Therapeutic-advances

vimarsana © 2020. All Rights Reserved.